Evidence map›Paper›PMID 25802735›Full record

ArticleMolecular autism2014

Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene.

Dea Adamsen, Vincent Ramaekers, Horace Tb Ho, Corinne Britschgi, Véronique Rüfenacht, David Meili, Elise Bobrowski, Paule Philippe, Caroline Nava, Lionel Van Maldergem and 5 more

Open access · goldAbstract read
In one paragraph

Article in Molecular autism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 72 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Organic Cation Transporters in Psychiatric Disorders.Handbook of experimental pharmacology · 2021
    Article
  15. General Overview of Organic Cation Transporters in Brain.Handbook of experimental pharmacology · 2021
    Article
  16. Review
  17. Article
  18. Article
  19. HistamineInternational journal of molecular sciences · 2019
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Dea Adamsen *Division of Metabolism, Department of Pediatrics, University of Zürich, Zürich 8032, Switzerland.
Vincent Ramaekers *Centre of Autism Liège and Division of Pediatric Neurology, University Hospital Liège, Liège 4000, Belgium.
Horace Tb HoDepartment of Pharmaceutics, University of Washington, Seattle 98195, WA, USA.
Corinne BritschgiDivision of Clinical Chemistry and Biochemistry, Department of Pediatrics, University of Zürich Zürich 8032, Switzerland.
Véronique RüfenachtDivision of Metabolism, Department of Pediatrics, University of Zürich, Zürich 8032, Switzerland.
David MeiliDivision of Clinical Chemistry and Biochemistry, Department of Pediatrics, University of Zürich Zürich 8032, Switzerland.
Elise BobrowskiUniversity Clinics of Child and Adolescent Psychiatry, University of Zürich, Zürich 8050, Switzerland.
Paule PhilippeCentre of Autism Liège and Division of Pediatric Neurology, University Hospital Liège, Liège 4000, Belgium.
Caroline NavaDepartment of Genetics, Cytogenetics and human Genetics, Pitié-Salpêtrière Hospital, Paris 75651, France.
Lionel Van MaldergemCentre for Human Genetics, University of Franche-Comté, Besançon 25030, France.
Rémy BruggmannFunctional Genomics Center Zürich, ETH Zürich/University of Zürich, Zürich 8057, Switzerland.
Susanne WalitzaUniversity Clinics of Child and Adolescent Psychiatry, University of Zürich, Zürich 8050, Switzerland.
Joanne WangDepartment of Pharmaceutics, University of Washington, Seattle 98195, WA, USA.
Edna GrünblattUniversity Clinics of Child and Adolescent Psychiatry, University of Zürich, Zürich 8050, Switzerland.
Beat ThönyDivision of Metabolism, Department of Pediatrics, University of Zürich, Zürich 8032, Switzerland.
University of Zurich · CHUniversity of Washington · USSorbonne Université · FRUniversité de franche-comté · FR

Funding

The plasma membrane monoamine transporter (PMAT): expression and role in mIBG disposition in neuroblastomaR01GM066233 · NIGMS · UNIVERSITY OF WASHINGTON · PI WANG, JOANNE · 2002 to 2020
$5.1M
NIGMS NIH HHS R01 GM066233
6 · The paper itself

Abstract

backgroundPatients with autism spectrum disorder (ASD) may have low brain serotonin concentrations as reflected by the serotonin end-metabolite 5-hydroxyindolacetic acid (5HIAA) in cerebrospinal fluid (CSF).

methodsWe sequenced the candidate genes SLC6A4 (SERT), SLC29A4 (PMAT), and GCHFR (GFRP), followed by whole exome analysis.

resultsThe known heterozygous p.Gly56Ala mutation in the SLC6A4 gene was equally found in the ASD and control populations. Using a genetic candidate gene approach, we identified, in 8 patients of a cohort of 248 with ASD, a high prevalence (3.2%) of three novel heterozygous non-synonymous mutations within the SLC29A4 plasma membrane monoamine transporter (PMAT) gene, c.86A > G (p.Asp29Gly) in two patients, c.412G > A (p.Ala138Thr) in five patients, and c.978 T > G (p.Asp326Glu) in one patient. Genome analysis of unaffected parents confirmed that these PMAT mutations were not de novo but inherited mutations. Upon analyzing over 15,000 normal control chromosomes, only SLC29A4 c.86A > G was found in 23 alleles (0.14%), while neither c.412G > A (<0.007%) nor c.978 T > G (<0.007%) were observed in all chromosomes analyzed, emphasizing the rareness of the three alterations. Expression of mutations PMAT-p.Ala138Thr and p.Asp326Glu in cellulae revealed significant reduced transport uptake activity towards a variety of substrates including serotonin, dopamine, and 1-methyl-4-phenylpyridinium (MPP(+)), while mutation p.Asp29Gly had reduced transport activity only towards MPP(+). At least two ASD subjects with either the PMAT-Ala138Thr or the PMAT-Asp326Glu mutation with altered serotonin transport activity had, besides low 5HIAA in CSF, elevated serotonin levels in blood and platelets. Moreover, whole exome sequencing revealed additional alterations in these two ASD patients in mainly serotonin-homeostasis genes compared to their non-affected family members.

conclusionsOur findings link mutations in SLC29A4 to the ASD population although not invariably to low brain serotonin. PMAT dysfunction is speculated to raise serotonin prenatally, exerting a negative feedback inhibition through serotonin receptors on development of serotonin networks and local serotonin synthesis. Exome sequencing of serotonin homeostasis genes in two families illustrated more insight in aberrant serotonin signaling in ASD.

Indexed as

Autism spectrum disorderPMATSerotonin end-metabolite 5-hydroxyindolacetic acidSERT

Identifiers

PMID25802735
PMCPMC4370364
OpenAlexW2143871231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.